Red Cross Asks FDA To Let False-Positive Blood Donors Back In The Pool
This article was originally published in The Gray Sheet
Executive Summary
FDA should include blood donor re-entry algorithms under investigational new drug applications for nucleic acid test (NAT) screening for hepatitis C (HCV) and HIV, according to the American Red Cross.
You may also be interested in...
Chiron/Gen-Probe Procleix HIV/HCV NAT Test To Cost $10-15 Per Screen
FDA is preparing to release a draft guidance on nucleic acid test (NAT) screening of whole blood samples following approval of Chiron and Gen-Probe's Procleix HIV-1/HCV NAT assay on Feb. 28
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.